407 related articles for article (PubMed ID: 26384446)
21. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP
Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488
[TBL] [Abstract][Full Text] [Related]
22. Serological responses of mares and weanlings following vaccination with an inactivated whole virus equine herpesvirus 1 and equine herpesvirus 4 vaccine.
Foote CE; Love DN; Gilkerson JR; Whalley JM
Vet Microbiol; 2002 Aug; 88(1):13-25. PubMed ID: 12119135
[TBL] [Abstract][Full Text] [Related]
23. TLR-5 agonist Salmonella abortus equi flagellin FliC enhances FliC-gD-based DNA vaccination against equine herpesvirus 1 infection.
Zhao Y; Chang J; Zhang B; Tong P; Wang C; Ran D; Su Y
Arch Virol; 2019 May; 164(5):1371-1382. PubMed ID: 30888564
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
[TBL] [Abstract][Full Text] [Related]
25. Application of a type-specific enzyme-linked immunosorbent assay for equine herpesvirus types 1 and 4 (EHV-1 and -4) to horse populations inoculated with inactivated EHV-1 vaccine.
Yasunaga S; Maeda K; Matsumura T; Kondo T; Kai K
J Vet Med Sci; 2000 Jul; 62(7):687-91. PubMed ID: 10945284
[TBL] [Abstract][Full Text] [Related]
26. Mitigation of pyrexia by a Th-1-biased IgG subclass response after infection with equine herpesvirus type 1 in horses pre-immunized with inactivated vaccine.
Bannai H; Tsujimura K; Kondo T; Nemoto M; Yamanaka T; Sugiura T; Kato T; Maeda K; Matsumura T
J Vet Med Sci; 2012 Jun; 74(6):791-5. PubMed ID: 22230983
[TBL] [Abstract][Full Text] [Related]
27. Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpesvirus 1 and 4 combination vaccine.
Heldens JG; Kersten AJ; Weststrate MW; van den Hoven R
Vet Q; 2001 Nov; 23(4):210-7. PubMed ID: 11765243
[TBL] [Abstract][Full Text] [Related]
28. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the molecular detection of vaccine-derived equine herpesvirus type 1 in blood and nasal secretions from horses following intramuscular vaccination.
Pusterla N; Chaney KP; Maes R; Wise AG; Holland R; Schott HC
J Vet Diagn Invest; 2007 May; 19(3):290-3. PubMed ID: 17459860
[TBL] [Abstract][Full Text] [Related]
30. Equine herpesvirus-1-specific interferon gamma (IFNgamma) synthesis by peripheral blood mononuclear cells in thoroughbred horses.
Luce R; Shepherd M; Paillot R; Blacklawst B; Wood JL; Kydd JH
Equine Vet J; 2007 May; 39(3):202-9. PubMed ID: 17520969
[TBL] [Abstract][Full Text] [Related]
31. Equine herpesvirus type 1 (EHV-1) replication at the upper respiratory entry site is inhibited by neutralizing EHV-1-specific IgG1 and IgG4/7 mucosal antibodies.
Eady NA; Holmes C; Schnabel C; Babasyan S; Wagner B
J Virol; 2024 Jun; 98(6):e0025024. PubMed ID: 38742875
[TBL] [Abstract][Full Text] [Related]
32. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus).
Fitzpatrick DR; Studdert MJ
Am J Vet Res; 1984 Oct; 45(10):1947-52. PubMed ID: 6208822
[TBL] [Abstract][Full Text] [Related]
33. Successful control of winter pyrexias caused by equine herpesvirus type 1 in Japanese training centers by achieving high vaccination coverage.
Bannai H; Mae N; Ode H; Nemoto M; Tsujimura K; Yamanaka T; Kondo T; Matsumura T
Clin Vaccine Immunol; 2014 Aug; 21(8):1070-6. PubMed ID: 24872513
[TBL] [Abstract][Full Text] [Related]
34. Induction of a Th-1-biased IgG subclass response against equine herpesvirus type 1 in horses previously infected with type 4 virus.
Bannai H; Tsujimura K; Kondo T; Nemoto M; Yamanaka T; Sugiura T; Maeda K; Matsumura T
J Vet Med Sci; 2011 Apr; 73(4):535-9. PubMed ID: 21139350
[TBL] [Abstract][Full Text] [Related]
35. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse.
Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM
Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414
[TBL] [Abstract][Full Text] [Related]
36. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
[TBL] [Abstract][Full Text] [Related]
37. Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses.
Ellis JA; Bogdan JR; Kanara EW; Morley PS; Haines DM
J Am Vet Med Assoc; 1995 Mar; 206(6):823-32. PubMed ID: 7538990
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection.
Patel JR; Didlick S; Bateman H
Equine Vet J; 2004 Jul; 36(5):447-51. PubMed ID: 15253088
[TBL] [Abstract][Full Text] [Related]
39. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N
Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683
[TBL] [Abstract][Full Text] [Related]
40. Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart.
Allkofer A; Garvey M; Ryan E; Lyons R; Ryan M; Lukaseviciute G; Walsh C; Venner M; Cullinane A
Arch Virol; 2021 Feb; 166(2):571-579. PubMed ID: 33410993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
